Глава 2. Антипсихотические препараты.

Литература.

Механизм действия.

Hyman SE, Nestler EJ. Molecular foundations of psychiatry. Washington, DC: American Psychiatric Press, 1993.

Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT₂ and D₂ receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286.

Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D₂ and 5-HT_2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156:869.

Tamminga CA. Principles of the pharmacotherapy of schizophrenia. In: Charney DS, Nestler EJ, Bunnery BS, eds. Neurobiology of mental illness. New York: Oxford University Press, 1999.

Шизофрения и шизоаффективное расстройство.

American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (4 suppl).

Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20.

Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 1999; 46:1388.

Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-refractory schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789.

Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46:1396.

Harder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825.

Robinson DG, Woerner MG, Alvir JMJ, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156:544.

Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54:549.

Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457.

Viguera AC, Baldessarini RJ, Hegarty JM, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54:49.

Аффективные расстройства.

Tohen M, Sanger TM, McElroy SL, et al. Olanzepine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156:702.

Zarate СA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56:411.

Другие психические и неврологические расстройства.

Goldberg SC, Schulz С, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. placebo. Arch Gen Psychiatry 1986; 43:680.

Pfeiffer RF, Kang J, Graber B, et al. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990; 5:239.

Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette syndrome. Arch Gen Psychiatry 1989; 46:722.

Атипичные антипсихотики.

Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329:162.

Brier AF, Malhotra AK, Su T-P, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999; 156:294.

Kane J, Honigfeld G, Singer J, et al. The Clozaril Collaborative Study Group: clozapine for the treatment-resistant schizophrenic. A double-blind comparison vs. chlorpromazine/benztropine. Arch Gen Psychiatry 1988; 45:769.

Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156:79.

Small JG, Hirsch SR, Arvantis LA, et al. Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997; 54:549.

Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156:990.

Wirshing DA, Marshall BD, Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999; 156:1374.

Антипсихотики-депо.

Carpenter WT Jr, Buchanan RW, Kirkpatrick B, et al. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 1999; 156:412.

Побочные эффекты и токсичность.

Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686.

Arana GW, Goff D, Baldessarini RJ, et al. The effect of anticholinergic prophylaxis on neuroleptic-induced dystonia. Am J Psychiatry 1988; 145:993.

Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57(suppl 11 ):40.

Chouinard G, Annable L, Ross-Choiunard A, et al. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8(suppl):21.

Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990; 10:12.

Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987; 144:673.

Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151:836.

Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146:717.

Rosenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989; 149:1927.

Лекарственные взаимодействия.

Ciraulo D, Shader RI, Greenblatt DJ, et al. Drug interactions in psychiatry. Baltimore: Williams & Wilkins, 1995.

Применение у пожилых.

Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47:7l6.

Применение при беременности.

Cohen LS, Altshuler LL. Pharmacologic management of psychiatric illness during pregnancy and the postpartum period. Psychiatr Clin North Am 1997; 21:60.

Romeau-Rouguette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977; 15:57.

Sloane D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977; 128:486.

Spielvogel A, Wile J. Treatment and outcomes of psychotic patients during pregnancy and childbirth. Birth 1992; 19:3.

Viguera AC, Baldessarini RC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52:189.